NCT04495127View on ClinicalTrials.gov

Selumetinib Paediatric NF1 Japan Study

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

March 24, 2023

Conditions

Neurofibromatosis Type 1

Interventions

DRUG

Selumetinib

Selumetinib 25 mg/m2 BID

Trial Locations (3)

105-8471

Research Site, Minatoku

466-8560

Research Site, Nagoya

157-8535

Research Site, Setagaya-ku

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY